Metastatic in Medical News

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

... therapy. A total of twenty-seven women with metastatic breast cancer were enrolled to the Phase 1B ... clinical activity among a cohort of patients with metastatic breast cancer who had been heavily pretreated ... of women who have been heavily pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, ...

AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

... alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer ... alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer ... erlotinib in patients with locally advanced or metastatic NSCLC after failure of at least one prior ...

Chicago team uses artificial intelligence to diagnose metastatic cancer

... of the lymph nodes revealed that 20 of them had metastatic cancer and 30 of them had cancer that remained ... computer would have accurately identified the 20 metastatic cases based on analyzing the ultrasound images of ... the program's potential for diagnosing metastatic disease. "We discovered that a computer ...

Delcath Systems Provides Update on Progress

... platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's ... Additional Patients for Enrollment in Phase III metastatic Melanoma Trial Since Late April, Enrolled ... patient enrollment milestones in our Phase III metastatic Melanoma Trial. Based on recent trends, we ...

Genetic testing may be valuable in treating colorectal cancer

... For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan ... for pretreatment pharmacogenetic testing for metastatic colorectal cancer, but remains to be verified by ... with irinotecan) chemotherapy regimen for metastatic colorectal cancer. The model assumed that under ...

Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018

... Emerging Therapies to Treat metastatic Hormone-Refractory Prostate Cancer Will Capture ... by the launch of emerging therapies in the metastatic hormone-refractory population, most notably ... Prostate Cancer finds that therapies in the metastatic hormone-refractory population -- for which there ...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

... randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of ... in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings ... patients. These patients had locally advanced or metastatic HER-2 negative breast cancer and had received no ...

US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

... Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, ... which is a very promising new treatment for metastatic triple negative breast cancer," says Dr. ... or without BSI-201. Patients must have measurable metastatic breast cancer with zero to two prior chemotherapy ...

Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)

... gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFr ... to include that retrospective subset analyses of metastatic colorectal cancer trials have not shown a ... pre-treatment work-up for patients diagnosed with metastatic colorectal cancer. About Colorectal ...

Rare Cells Linked to Pediatric Cancers

... children with localized cancer, 22 children with metastatic cancer and 20 healthy children. Circulating ... in strikingly higher amounts in patients with metastatic disease," Francoise Farace, director of the ... Research. The finding that children with metastatic cancer had much higher levels of these cells than ...

Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)

... as a maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC), specifically ... treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy treatment.(4) ... as a first-line treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology. ...

Predicting the return of prostate cancer: New Johns Hopkins study betters the odds of success

... eight and 10, were twice as likely to develop metastatic cancer. In men whose PSA became detectable ... were more than 20 times more likely to develop metastatic cancer than men whose PSA look longer than 15 ... "watch and wait" until imaging scans can locate metastatic disease. ...

Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen

... of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial ... study ever conducted in the indication of metastatic treatment of bladder cancer after failure of a ... the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial ...

Lab Study Finds Protein That May Inhibit Cancer Spread

... Hospital Boston had found previously that metastatic tumors prepare "landing places" for cancer in ... localized prostate and breast tumors but that metastatic tumors secreted very little of the protein. The researchers then added prosaposin to highly metastatic tumor cells and injected them into mice. Lung ...

Potent metastasis inhibitor identified

... Program at Children's, has been finding that metastatic tumors prepare landing places in distant organs ... high levels of prosaposin, they found, while metastatic tumors secreted very little. When the researchers ... stroma, might be an effective way to inhibit the metastatic process in humans," says Watnick. If this ...

Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

... efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online ... agent designed to seek-out and destroy metastatic cancers that have spread throughout the body, ... By validating the potential of Rexin-G to control metastatic cancer with single-agent efficacy, whereas other ...

Vaccine shows therapeutic promise against advanced melanoma

... survival rates for those with regional and metastatic disease are 65 percent and 16 percent, ... (IL-2) showed response rates of 42 percent in metastatic melanoma patients, a Phase III randomized trial ... were enrolled in the study. All had advanced metastatic melanoma and were stratified for cutaneous ...

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

... 2 study of OGX-011 in patients with advanced metastatic prostate cancer and Phase 1 study of OGX-427 in ... 2 trial of OGX-011 in patients with advanced metastatic prostate cancer. In this trial, OncoGenex ... standard of care for patients with advanced metastatic prostate cancer. In addition, OncoGenex reported ...

Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting

... Activation in Circulating Tumor Cells (CTCs) in metastatic Tumors Using Proximity Mediated Microarray ... platform. Further, an analysis of CTCs from metastatic breast cancer patients showed that more than 50% ... in a clinical setting with an initial focus on metastatic breast cancer. The Company submitted an ...

Pitt melanoma researchers present novel findings at ASCO

... 70,000 people will be diagnosed with metastatic melanoma this year," said principal investigator ... examined the tumor tissues of 21 patients with metastatic melanoma, some of whom responded to chemotherapy ... likelihood of responding to treatment for metastatic melanoma." The results of this study are being ...

Avastin Shows No Benefit Against Early Stage Colon Cancer

... drug Avastin, widely used for lung, breast and metastatic colorectal cancers, appears ineffective for ... as Avastin], we definitely see improvements with metastatic cancer if we continue giving the drug," Chung ... the notion that patients newly diagnosed with metastatic colorectal cancer should get surgery right away. ...

ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer

... the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with other ... as a first-line treatment for locally-advanced or metastatic nonsquamous NSCLC for patients, and it is ... treatment of patients with locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy. ...

Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer

... Docetaxel/Prednisone as First-Line Therapy for metastatic Castration-Resistant Prostate Cancer - - ... 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) ... prednisone is active as first-line therapy for metastatic CRPC. This was demonstrated by several endpoints, ...

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer

... trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another ... combination of therapies in patients with HER2+ metastatic breast cancer, researchers say. The chemotherapy ... with Herceptin) that are currently used to treat metastatic HER2+ breast cancer is about 50 percent, Dr. Tan ...

BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting

... updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American ... encoding, oncolytic herpes virus in unresectable metastatic melanoma," at ASCO on Monday, June 1, 2009 from ... can be used for regulatory approval. About metastatic Melanoma According to the American Cancer ...

Triple drug combination is promising option to treat metastatic HER2+ breast cancer

... trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another ... combination of therapies in patients with HER2+ metastatic breast cancer, researchers say. The chemotherapy ... with Herceptin) that are currently used to treat metastatic HER2+ breast cancer is about 50 percent, Dr. Tan ...

Amgen Highlights Data to Be Presented at ASCO

... panitumumab monotherapy findings, it appears that metastatic colorectal cancer (mCRC) patients with wild-type ... of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M ... (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC) Lead ...

NYU Langone Medical Center's tip sheet to the 45th Annual Meeting of ASCO

... drug is promising in animal studies of metastatic melanoma Seth J. Orlow, M.D., Ph.D., the ... in animal studies as a potential treatment for metastatic melanoma. Researchers from NYU Langone Medical ... the drug's effectiveness in patients with metastatic melanoma. Abstract # 9006, 1:30 p.m. on ...

Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche

... on the permissive microenvironment, or the metastatic niche, that forms in particular tissues located ... full metastasis takes hold. "In cancer, it is metastatic disease that causes morbidity and mortality," ... cancer treatments that target each step along the metastatic pathway. "We can envision a time in the ...

Sanofi-aventis Announces Good First-quarter 2009 Performance

... as an adjuvant and as first line treatment in the metastatic phase, were up 3.0% at euro 266 million in the ... the treatment of triple-negative metastatic breast cancer, ovarian cancer, and other types ... cancer. The results of the triple-negative metastatic breast cancer Phase II trial will ...

Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08

... also announced that Phase 2 programs in NSCLC in metastatic breast cancer have been completed. The results ... alone in patients with previously untreated metastatic colorectal cancer ('203 study). The review of the ... alone in patients with previously treated metastatic colorectal cancer ('181 study). In addition, a ...

Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer

... most influences their prescribing decisions in metastatic triple-negative breast cancer. Clinical data and ... Avastin and Taxol. The new report entitled metastatic Triple-Negative Breast Cancer: Physicians Want ... patients would earn a 65 percent patient share in metastatic triple-negative breast cancer in the United ...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability

... cell lung cancer (SCLC) and in Phase 2 trials in metastatic colorectal cancer (CRC) and metastatic castration-resistant prostate cancer (CRPC). ... Phase 2 clinical trials -- one in patients with metastatic CRC and the other in patients with ...

New test may predict spread of breast cancer

... This might spare many women at low risk for metastatic disease from undergoing unnecessary and ... is the first marker that could reliably predict metastatic outcome in a case-controlled study, says study ... 40 percent of these patients actually do develop metastatic disease. What this means is that most of these ...

Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports

... with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ... information(4) In Phase III unresectable or metastatic GIST trials (400 mg/day; 800 mg/day), severe (NCI ... In the Phase III unresectable or metastatic GIST studies, 13% of patients reported (NCI ...

Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City

... PHP System(TM) and the Company's Phase III metastatic Melanoma Study, currently enrolling at eleven ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have ... Systems, stated, "Delcath's pivotal Phase III metastatic Melanoma Study has experienced significant ...

Survey of metabolites finds new prostate cancer marker

... changes as cancer develops and progresses to metastatic disease. Chinnaiyan's lab, which has extensively ... tissue, clinically localized prostate cancer, and metastatic prostate cancer. Sixty metabolites were present ... localized disease and very highly elevated in metastatic cancer. They confirmed these dramatic ...

AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer

... by 2012 and through 2017 for the treatment of metastatic hormone-refractory prostrate cancer due to its ... Taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," ... Resources. The new report entitled metastatic Hormone-Refractory Prostate Cancer: Physicians ...

Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin

... 2 trial of picoplatin in patients with metastatic CRC at the American Society of Clinical ... for the first-line treatment of metastatic CRC in 101 patients who have not ... 2 trial of picoplatin in patients with metastatic HRPC at ASCO's 2009 Genitourinary Cancers ...

Lung cancer cells activate inflammation to induce metastasis

... inflammatory microenvironment hospitable for the metastatic spread of lung cancer. The discovery could lead ... approach to identify proteins produced by metastatic cancer cells that are responsible for generation ... they screened for factors produced by metastatic cancer cells in mice that could stimulate the ...